clinical trial · NCT07074418
Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2
Chronic Kidney DiseasesEmpagliflozin 10 MG then PlaceboPlacebo then Empagliflozin 10 MG
brief summary
The proximal tubule remains the main site for sodium reabsorption in patients with advanced renal failure. The investigators therefore hypothesize that SGLT2i should still exert a significant natriuretic effect in patients with eGFR below 20 ml/min/1.73m2, and therefore should still decrease proteinuria with a potential renal protective effect.
started
Apr 1, 2026
primary completion
Dec 1, 2027
completion
Dec 1, 2027
last updated
Jan 23, 2026
official title
Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2 - EMPA [10-20]
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol